An update on the clinical utility of extracorporeal photopheresis in the treatment of graft-versus-host disease

Baheyeldin Salem1,2
Jennifer Webb3
David Alex Jacobsohn1,2
1Blood and Marrow Transplant Program, 2Department of Pediatrics, 3Department of Transfusion Medicine, Children’s National Health System, Washington, DC, USA

Abstract: Graft-versus-host disease (GVHD) continues to be a major complication following allogeneic hematopoietic cell transplantation (allo-HCT) with high morbidity and mortality. Corticosteroids are the first-line treatment for GVHD; however, a substantial number of patients go on to require second-line treatment where no single therapeutic modality has been proven to be the most effective. Extracorporeal photopheresis (ECP) is an efficient and established therapy for cutaneous T-cell lymphoma, GVHD, rejection after solid organ transplantation and various autoimmune diseases. Although large randomized trials are limited, there is compelling cumulative data on the efficacy of ECP for GVHD, and the response rates, especially for cutaneous involvement, are encouraging. ECP has an excellent safety profile, a well-documented steroid-sparing effect, proven survival benefit and overall quality-of-life improvement. In many institutions, ECP is commonly regarded as the preferred second-line treatment for GVHD.

Keywords: GVHD, ECP, immunosuppressive therapy, IST, apheresis, steroid-refractory graft-versus-host disease, hematopoietic cell transplantation, graft versus leukemia effect

Introduction

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only known curative therapeutic modality for various malignant and nonmalignant disorders. Despite recent advances in conditioning regimens, human leukocyte antigen (HLA)-matching procedures and supportive care, there remains a substantial morbidity and mortality associated with HCT. Nonrelapse mortality is largely attributable to graft-versus-host disease (GVHD), both acute and chronic forms of the disease.1,2

In an analysis of 1,270 patients surviving >2 years after allo-HCT, GVHD accounted for 12% of deaths surpassed only by recurrence of primary disease3 and up to 15% of deaths following unrelated donor transplant.4

Systemic immunosuppressive therapy (IST) remains the standard approach for the treatment of GVHD, the duration of which can be prolonged particularly in chronic GVHD (cGVHD), which occurs in ~50% of patients.5,6 Corticosteroids remain the standard first-line IST for GVHD.7–9 This pharmacological approach is effective only in ~50% of patients;10 moreover, its use is limited by toxicity.

Despite a wide variety of second-line systemic IST options, there is no standard of care for those who do not respond to steroids as first-line treatment.11 Patients with steroid-refractory (SR) acute GVHD (aGVHD) or cGVHD are frequently offered participation in clinical trials if possible to help identify optimal second-line therapy. If trials are unavailable or patients are ineligible, the choice of second-line therapy is largely based on institutional practices and physician preference. Extracorporeal...
phoptopheresis (ECP) offers a potential therapeutic advantage in patients with GVHD.12,13 In 1994, Owisanowski et al14 reported the first case of cGVHD successfully treated with ECP. The authors reported a case of a 43-year-old female with acute myeloid leukemia (AML) who developed cGVHD with severe sclerodermatous manifestations that was successfully treated with ECP after lack of response to cyclosporine, low-dose steroids and psoralen ultraviolet A (PUVA) therapy.

ECP is an apheresis-based immunomodulatory therapy. Whole blood is removed from the patient, and centrifugation is used to separate out the leukocyte-enriched buffy coat, rich with peripheral blood mononuclear cells (PBMCs). These cells are exposed to the photosensitizing drug 8-methoxypsoralen (8-MOP) and are then irradiated with ultraviolet A (UV A) light. The photoactivated buffy coat is then re-infused into the patient.

The type of vascular access necessary to complete a course of ECP is determined by multiple factors, including patient size, anticipated duration of procedures, need for a blood prime and adequacy of peripheral access. Though older adolescents and adults may be able to tolerate ECP using peripheral veins, the frequency and duration of therapy often necessitate a central line in younger children. For those patients who are <40 kg and therefore require a blood prime, manufacturer guidelines recommend double-lumen, apheresis-compatible access (Therakos, Inc. Westchester, PA, USA).

The technology and equipment involved with ECP therapy have evolved. Originally, ECP was a discontinuous or “offline” apheresis procedure that involved separate collection, activation and infusion steps. External UVA irradiation is applied after collection, which has been performed on the Amicus, Optia and Cobe Spectra platforms. However, modern machines use intermittent or continuous PBMC collection techniques and are able to phototivate and infuse all with the same machine. This is considered an “online” technique. This technology was developed by Therakos, Inc. with a majority of the procedures in the United States involving the Therakos Uvar XTS system (second-generation model). This machine uses an intermittent separation process, which may be problematic in patients weighing <40 kg or those with a pre-procedural hematocrit <30% because of the volume of extracorporeal blood required. More recently, in 2009, the third-generation Therakos Cellex device has become available with advances including continuous-flow separation technology, shorter treatment times (1.5 versus 3 hours) and reduced extracorporeal blood volumes allowing for lower weight patients to safely undergo the procedure.15 Brosig et al prospectively compared offline versus online systems. Notable differences were seen in the cellular composition of the two methods. Offline methods collecteduffy coats that were enriched with CD16+ mononuclear cells. In contrast, online method displayed enrichment of nonclassical monocytes. However, the clinical significance of these findings is unclear.16

Our group here at Children’s National compared the two most frequently used instruments, the Uvar XTS and Cellex, by performing a retrospective analysis of 10 pediatric patients who have received ECP for SR-GVHD (both acute and chronic). Compared to the Uvar XTS1 instrument, use of the Cellex instrument resulted in shorter runtimes, increased percentage of mononuclear cells treated, reduced incidence of line occlusions requiring tissue plasminogen activator (TPA) treatment and decreased incidence of patient-related complications.17

ECP received US Food and Drug Administration (FDA) approval in the late 1980s for the palliative treatment of skin manifestations in patients with cutaneous T-cell lymphoma (CTCL) unresponsive to other forms of treatment. In this disease, ECP is thought to elicit an immunostimulatory effect against neoplastic cells.18

The precise mechanism by which ECP improves outcomes in GVHD is unknown. During ECP, PBMCs are exposed to 8-MOP that covalently binds and cross-links DNA upon exposure to UVA light irradiation resulting in apoptosis. This appears to exert an immunomodulatory effect against T-cell-mediated disorders such as GVHD.19–25 It is believed that ECP-induced lymphocyte apoptosis stimulates the differentiation of monocytes into immature dendritic cells (DCs) that can then become active antigen-presenting cells (APCs) and cytokine producers.26 Reports of cytokine responses post ECP have demonstrated an increased production of immunosuppressive cytokines interleukin (IL)-10 and IL-1 Ra.27 APCs that have phagocytized apoptotic T-cells present antigen to T-cells in lymph nodes and spleen, which results in antigen-specific T-regulatory cells (T-regs) that are specific for the pathogenic T-cell clones. This downregulation of alloreactivity of T-lymphocytes by ECP was demonstrated in several early in vitro studies that have showed inactivation of T-lymphocytes by treatment with 8-MOP and UVA.28–35 This has been confirmed in an experimental bone marrow transplant (BMT) murine model, where the photoinactivation of donor cells with 8-MOP and UVA prior to infusion prevented the onset of GVHD.36

**Clinical experience for aGVHD**

To date, there is no optimal or standard therapeutic option for second-line treatment of SR-aGVHD. Despite a large
number of studies, choice of second-line agent/therapy varies between institutions and among different transplant physicians. Table 1 summarizes the outcome to ECP use as a second-line treatment for aGVHD.

In 2012, Martin et al\textsuperscript{11} published recommendations of the American Society of Blood and Marrow Transplantation for the treatment of aGVHD based on a comprehensive and critical review of published reports. Across the 67 selected studies, data on complete response (CR) and partial response (PR) of aGVHD and 6-month survival did not support the choice of any specific agent for second-line therapy. Besides horse antithymocyte globulin (ATG), ECP was the most frequently studied therapeutic option.

Messina et al\textsuperscript{15} treated 33 patients with aGVHD at four pediatric hospitals where they observed a CR of 76% in skin, 60% in the liver and 75% in gastrointestinal (GI) tract. The 5-year overall survival (OS) was 69% among responders versus 12% for nonresponders ($p = 0.001$).

Greinix et al\textsuperscript{18} conducted a prospective Phase II study on ECP in 59 adult patients with severe aGVHD. Compared to the pilot study, intensification of ECP therapy to two to three treatments per week on a weekly basis was performed. Compared to the pilot study, this regimen led to improved CR rates in patients with grade IV aGVHD (60% versus 12%) and GI involvement (73% versus 25%). Overall CR rates were 82%, 60% and 61% in patients with skin, GI and liver aGVHD. In patients who responded to ECP, steroids could be discontinued at a median of 55 days (range 17–287 days) after start of ECP. In univariate analysis, a lower grade of aGVHD, fewer organs involved at the start of first-line therapy with corticosteroids as well as at the start of ECP, and a lower cumulative corticosteroid dose prior to ECP, significantly increased the probability of achieving a CR. However, after multivariate logistic regression analysis, only a lower grade of aGVHD at the start of ECP and later onset of corticosteroid medication after HSCT were variables significantly favoring the achievement of CR by ECP.

Jagasia et al\textsuperscript{19} compared ECP to anticytokine therapy consisting of inolimumab or etanercept as second-line treatment for SR-aGVHD patients. Fifty-seven patients received ECP compared to 41 patients receiving anticytokine treatment. Rate of CR was significantly higher in the ECP cohort compared to the anticytokine therapy cohort (54% versus 20%, $p = 0.001$), respectively. In multivariable analyses, ECP, adjusted for corticosteroid dose and grade of aGVHD, was an independent predictor of response and was associated with superior survival (hazard ratio [HR] 4.6, $p = 0.016$) in patients with corticosteroid-refractory aGVHD grade II.

In addition to its use as a second-line treatment for GVHD, preliminary studies have evaluated the role of ECP as a preventative approach for GVHD and as a part of myeloablative conditioning regimen. Shaughnessy et al\textsuperscript{40} assessed the effectiveness of ECP for the prevention of aGVHD in a Phase II multicenter study where ECP was administered to 62 patients before standard myeloablative conditioning regimen combined with cyclosporine A (CSA) and methotrexate for GVHD prophylaxis. Results were compared to the Center for International Blood and Marrow Transplant Research (CIBMTR) historical control group. Grades II–IV aGVHD developed in 22 (36%) of the 62 subjects, including nine (30%) of 30 related donor HCT recipients and 13 (41%) of 32 matched unrelated or one HLA-mismatched related donor HCT recipients. A 100-day cumulative incidence (CI) of aGVHD grades II–IV was reported as 35% and 1-year

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Study type</th>
<th>Patients (n)/patient population</th>
<th>% ORR</th>
<th>% CR/PR</th>
<th>% CR/PR</th>
<th>% CR/PR</th>
<th>% OS</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Messina et al (2003)</td>
<td>Retrospective</td>
<td>33/pediatric</td>
<td>76 (25/33)</td>
<td>75 (15/20)</td>
<td>60 (9/15)</td>
<td>69 at 5 years</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Garban et al (2005)</td>
<td>Pilot</td>
<td>12/adult</td>
<td>75 (9/12)</td>
<td>67 (8/12)</td>
<td>40 (2/5)</td>
<td>0 (0/2)</td>
<td>42</td>
<td>67</td>
</tr>
<tr>
<td>Greinix et al (2006)</td>
<td>Phase II</td>
<td>59/adult</td>
<td>82 (47/57)</td>
<td>60 (9/15)</td>
<td>60 (14/23)</td>
<td>47 at 5 years</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Berger et al (2007)</td>
<td>Retrospective</td>
<td>15/pediatric</td>
<td>67 (10/12)</td>
<td>85 (11/13)</td>
<td>60 (6/10)</td>
<td>71 (5/7)</td>
<td>67 (10/15)</td>
<td>68</td>
</tr>
<tr>
<td>Kanold et al (2007)</td>
<td>Prospective</td>
<td>12/pediatric</td>
<td>83 (10/12)</td>
<td>90 (9/10)</td>
<td>83 (5/6)</td>
<td>56 (5/9)</td>
<td>75 at 8.5 mo</td>
<td>57</td>
</tr>
<tr>
<td>Calore et al (2008)</td>
<td>Retrospective</td>
<td>15/pediatric</td>
<td>100 (15/15)</td>
<td>92 (12/13)</td>
<td>71 (10/14)</td>
<td>100 (1/1)</td>
<td>85 at 5 years</td>
<td>69</td>
</tr>
<tr>
<td>Perrotti et al (2010)</td>
<td>Prospective</td>
<td>50/pediatric</td>
<td>68 (34/50)</td>
<td>83 (39/47)</td>
<td>73 (8/11)</td>
<td>67 (16/24)</td>
<td>64 at 1 year</td>
<td>58</td>
</tr>
<tr>
<td>Gonzalez et al (2010)</td>
<td>Prospective</td>
<td>21/adult</td>
<td>90 (19/21)</td>
<td>66</td>
<td>60</td>
<td>39</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>Jagasia et al (2013)</td>
<td>Retrospective</td>
<td>57/adult</td>
<td>66</td>
<td>60</td>
<td>39</td>
<td>73</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Berger et al (2014)</td>
<td>Retrospective</td>
<td>34/mixed</td>
<td>65</td>
<td>60</td>
<td>39</td>
<td>73</td>
<td>73</td>
<td></td>
</tr>
</tbody>
</table>
CI of cGVHD as 38%. Compared to 347 matched historical controls from the CIBMTR, the ECP-treated cohort had a lower rate of grades II–IV aGVHD. Adjusted OS at 1 year was 83% in the ECP study group and 67% in the historical control group (relative risk 0.44). The results from this study support the prophylactic benefit of ECP as well as survival advantage over historical control that merits further evaluation as a preventive measure. Miller et al41 showed a lower than expected incidence of severe aGVHD when ECP was used as part of a novel reduced-intensity conditioning regimen with pentostatin and low-dose total body irradiation (TBI). The regimen had low incidence of transplant-related mortality and no negative effects on engraftment or disease relapse.

Kitko et al43 conducted a prospective Phase II clinical trial that incorporated tacrolimus, mycophenolate mofetil (MMF), etanercept and ECP as GVHD prophylaxis in 48 patients (median age = 60 years) undergoing reduced-intensity conditioning unrelated donor transplantation. Etanercept was administered twice weekly for 8 weeks after HCT, and ECP was given for 12 treatments, starting weekly on day 28 and tapering off by day 180. GVHD occurred before the initiation of ECP in 10 patients. Cumulative incidence of grades II–IV aGVHD was similar to historical controls. Subjects developed predominantly moderate grade GVHD, with high rates of steroid responsiveness (84% day 56 CR/PR rate). However, this strategy was not effective at preventing a high incidence of cGVHD that resulted in late deaths. The 2-year OS for patients in this study was 56%.

Conclusion
For patients with aGVHD who are SR or steroid dependent, there is no universally accepted therapy.11 Several agents with different mechanisms of action have been considered or continue to be evaluated as a second-line therapy (eg, anti-IL-2, anti-tumor necrosis factor [anti-TNF], anti-CD52, mycophenolate mofetil, tacrolimus, sirolimus, mesenchymal stromal cells and ECP). Several groups both in the US and in Europe are attempting to define the guidelines for use of ECP in aGVHD. Consensus statements are focused on patient selection for ECP treatment, protocol development for treatment schedules and durations, and response monitoring criteria. Das-Gupta et al43 published the UK consensus statement on the use of ECP in aGVHD. ECP is currently recommended as second-line therapy for patients with aGVHD, grades II–IV disease who are SR, steroid dependent or steroid intolerant. Two treatments/procedures of photopheresis on separate days should be initiated weekly for a minimum of eight cycles (8 weeks). Expected response rates vary by organ system involved, with skin GVHD having the highest overall response rate (ORR) of 60–80%. In a systematic review by Abu-Dalle et al,44 ORR for aGVHD was 0.69 with organ-specific response being the highest in cutaneous aGVHD (0.84 ORR) followed by GI GVHD (0.65 ORR). Patients with higher grade aGVHD may benefit from aggressive, up-front ECP with three treatments per week for the first 4 weeks. Patients who have progressive aGVHD during this time may require additional therapy at the discretion of the treating physician. Emerging data on use of ECP as primary prophylaxis for aGVHD are somewhat encouraging and warrant further investigation using large controlled prospective studies.

Clinical experience for cGVHD

cGVHD has been characterized historically by autoimmune and alloimmune dysregulation occurring after the first 100 days of allo-HCT.45,46 A newer set of diagnostic criteria have been developed, and the definition of cGVHD has been refined to include the development of diagnostic features of immune dysfunction that may be present before day 100 and almost always occur within 3 years posttransplant.2

The clinical management of patients with extensive cGVHD is challenging due to the wide variability of disease manifestations, clinical severity, secondary infectious complications and treatment-related toxicity.47 Table 2 summarizes the outcome to ECP use as a second-line treatment for cGVHD.

In 2008, Flowers et al48 published the first prospective, multicenter randomized controlled Phase II clinical trial assessing utility of ECP in patients with cGVHD who were mostly steroid dependent. The study focused on skin involvement in cGVHD using total skin score (TSS) to track changes in skin in both treatment group and control group after 12 weeks of therapy. Patients were randomized to receive conventional therapy alone or ECP plus conventional therapy. ECP was delivered three times during week 1 then twice weekly from week 2 through 12 (ECP-responsive patients received two more ECP treatments every 4 weeks until week 24). The changes in TSS from baseline up to week 12 between both groups were not statistically significant (−14.5% in ECP group and −8.5% in control group, \( \text{p} = 0.48 \)). At week 12, the proportion of patients who had at least a 25% decrease from baseline in TSS was 8.3% in the ECP group and 0% in the control group (\( \text{p} = 0.04 \)). Clinical findings in this trial suggest that ECP may have a steroid-sparing effect in cGVHD where, by week 12, 25.0% (\( n = 12 \)) of ECP-treated patients and 12.8% (\( n = 6 \)) of control-treated
patients had a 50% or greater reduction in the total daily dose of corticosteroids ($p = 0.13$). Findings also suggest that ECP resulted in a significant clinician-assessed disease response. In a follow-up study, Greinix et al\textsuperscript{49} further studied patients in the control group who were allowed to crossover to the ECP arm either before week 12 if they had progressive skin disease or after week 12 if inadequate skin response as defined by $<15\%$ improvement in the TSS compared with baseline or a $\leq25\%$ reduction in corticosteroid dose. Similar but less robust trend in clinical benefit to the original study was observed where median percent decrease in TSS from baseline to week 24 was $-25.8\%$. A 50% or more reduction in corticosteroid dose at week 24 was observed in $33\%$ of patients. For extracutaneous GVHD, clinical benefit was most robust in oral mucosa ($70\%$ complete and partial resolution at week 24). These studies, however, are limited in their generalization due to their use of TSS as the primary end point, which has not been validated. As the steroid taper was left to the discretion of individual providers, it is challenging to compare the relative ability of ECP to spare steroids since there was no standard schedule. It is also unclear if additional benefit would have been seen in extracutaneous GVHD if a longer course of ECP therapy had been continued.

In a large uncontrolled case series, Couriel et al\textsuperscript{50} noted a 61% response rate in 71 patients with SR-cGVHD with the best responses observed in skin, liver, oral mucosa and eye. A CR was achieved in $20\%$ of patients.

In 2016, Malagola et al\textsuperscript{51} published data of a multicenter retrospective analysis from The Italian Bone Marrow Transplant Group (Gruppo Italiano Trapianto di Midollo Osseo) supporting the use of ECP as a second-line treatment in patients with aGVHD and cGVHD. Forty-five patients had SR-aGVHD. Of those with aGVHD, 91% of patients achieved CR, but $33\%$ went on to develop cGVHD. OS for aGVHD at 20 months was $65\%$. Of the 49 patients with cGVHD, 45% and $35\%$ of patients with SR-cGVHD achieved CR and PR, respectively. OS for cGVHD patients at 27 months was $90\%$.

Foss et al\textsuperscript{52} reported an ORR of 64% in a prospective study on 25 patients with extensive SR cGVHD, and in $-80\%$ of patients, a reduction or discontinuation of IST was possible. These findings were similar to what was previously published by Seaton et al\textsuperscript{53} in 2003 where IST was stable or reduced in $86\%$ of patients. The group prospectively studied 28 patients with advanced cGVHD treated with ECP and observed response to ECP even in those patients with extensive cutaneous cGVHD of 2 years duration.

### Table 2 Published response rates for ECP as a second-line treatment for cGVHD

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Study type</th>
<th>Patients (n)/patient population</th>
<th>% ORR</th>
<th>% CR+PR</th>
<th>% CR+PR</th>
<th>% CR+PR</th>
<th>% OS</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greinix et al (1998)</td>
<td>Prospective</td>
<td>15/adult</td>
<td>93</td>
<td>100 (15/15)</td>
<td>90 (9/10)</td>
<td>100 (11/11)</td>
<td>93 (14/15)</td>
<td>74</td>
</tr>
<tr>
<td>Child et al (1999)</td>
<td>Prospective</td>
<td>11/adult</td>
<td>NA</td>
<td>100</td>
<td>17</td>
<td>100</td>
<td>82 (9/11)</td>
<td>75</td>
</tr>
<tr>
<td>Salvanschi et al (2001)</td>
<td>Prospective</td>
<td>14/pediatric</td>
<td>64 (9/14)</td>
<td>83 (10/12)</td>
<td>67 (6/9)</td>
<td>67 (8/12)</td>
<td>79 (11/14)</td>
<td>13</td>
</tr>
<tr>
<td>Messina et al (2003)</td>
<td>Retrospective</td>
<td>44/pediatric</td>
<td>74</td>
<td>57</td>
<td>60</td>
<td>60</td>
<td>77 (34/44)</td>
<td>37</td>
</tr>
<tr>
<td>Rubegni et al (2005)</td>
<td>Retrospective</td>
<td>32/adult</td>
<td>78 (25/32)</td>
<td>81 (22/27)</td>
<td>82 (18/22)</td>
<td>92</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>Garban et al (2005)</td>
<td>Prospective</td>
<td>15/mixed</td>
<td>87 (13/15)</td>
<td>100 (12/12)</td>
<td>33 (1/3)</td>
<td>NA</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Bisaccia et al (2006)</td>
<td>Retrospective</td>
<td>14/adult</td>
<td>NA</td>
<td>50 (7/14)</td>
<td>60 (3/5)</td>
<td>43 (3/7)</td>
<td>71 (10/14)</td>
<td>76</td>
</tr>
<tr>
<td>Courtel et al (2006)</td>
<td>Retrospective</td>
<td>71/mixed</td>
<td>61 (43/71)</td>
<td>57</td>
<td>71</td>
<td>78</td>
<td>18 (13/71)</td>
<td>50</td>
</tr>
<tr>
<td>Kanold et al (2007)</td>
<td>Retrospective</td>
<td>15/pediatric</td>
<td>73 (11/15)</td>
<td>75 (9/12)</td>
<td>82 (9/11)</td>
<td>86 (6/7)</td>
<td>67 (10/15)</td>
<td>57</td>
</tr>
<tr>
<td>Flowers et al (2008)</td>
<td>RCT</td>
<td>48/mixed</td>
<td>74 (32/43)</td>
<td>74 (32/43)</td>
<td>74 (32/43)</td>
<td>74 (32/43)</td>
<td>74 (32/43)</td>
<td>77</td>
</tr>
<tr>
<td>Jagasia et al (2009)</td>
<td>Retrospective</td>
<td>43/adult</td>
<td>69.5 (16/23)</td>
<td>83</td>
<td>100 (4/4)</td>
<td>80 (4/5)</td>
<td>82.6 at 5 years</td>
<td>58</td>
</tr>
<tr>
<td>Greinix et al (2011)</td>
<td>Prospective</td>
<td>29/adult</td>
<td>31 (9/29)</td>
<td>92 (57/62)</td>
<td>NA</td>
<td>91 (29/32)</td>
<td>77 (63/82)</td>
<td>10</td>
</tr>
<tr>
<td>Dignan et al (2012)</td>
<td>Retrospective</td>
<td>82 (69 evaluable)/adult</td>
<td>79 (65/82)</td>
<td>60 (27/45)</td>
<td>50 (10/20)</td>
<td>67 (18/27)</td>
<td>55 (32/58)</td>
<td>79</td>
</tr>
<tr>
<td>Hauntmann et al (2013)</td>
<td>Retrospective</td>
<td>32/adult</td>
<td>44 (14/32)</td>
<td>59 (10/17)</td>
<td>100 (1/1)</td>
<td>60 (3/5)</td>
<td>71/32</td>
<td>80</td>
</tr>
<tr>
<td>Malagola et al (2016)</td>
<td>Retrospective</td>
<td>49/adult</td>
<td>80</td>
<td>59 (19/32)</td>
<td>NA</td>
<td>NA</td>
<td>80 (44/49)</td>
<td>51</td>
</tr>
</tbody>
</table>

**Abbreviations:** cGVHD, chronic graft-versus-host disease; CR, complete response; ECP, extracorporeal photopheresis; NA, not available; ORR, overall response rate; OS, overall survival; PR, partial response; RCT, randomized controlled trial.
More recently, Dignan et al \(^4\) prospectively studied the impact of 6 months of treatment with ECP on skin scores and quality of life (QoL) in patients with SR-cGVHD. Seventy percent of patients had a CR or PR. Reduction in IST was achieved in 80% of patients. In a subset of patients who completed a QoL questionnaire using both the Lee chronic GVHD symptom scale and dermatology QoL index, both scores were significantly lower after 6 months of ECP (22 compared with 36, \(p = 0.012\) and 3.4 compared with 6.9, \(p = 0.009\)).

Two recent systematic reviews concluded that use of ECP in cGVHD can be effective, and in certain cases allows for discontinuation of IST. ORRs and organ-specific efficacy were similar between both studies (with GI and lung cGVHD showing less response to ECP treatment). In the study by Abu-Dalle et al, \(1\) ORR for cGVHD was 0.64. Response rates for cGVHD involving the skin and GI tract were 0.71 and 0.62, respectively; in contrast, the ORR for cGVHD involving the lungs was only 0.15. Additionally, ECP has been shown to be an extremely safe treatment modality. Concordant results were observed in the analysis by Malik et al \(^5\) where the pooled response rate for skin, oral, liver, musculoskeletal, ocular, GI, and lung, and SR-cGVHD was 74%, 72%, 68%, 64%, 60%, 53% and 48%, respectively.

Many investigators administered ECP in patients with cGVHD according to the original publication by Edelson et al \(^6\) where they administered two ECP treatments on consecutive days every 2–4 weeks. Therefore, cGVHD has been treated with four to eight treatments per month, usually for 12–24 weeks. Subsequent tapering of ECP treatments, in most centers, is largely influenced by the ability to reduce or withdraw concomitant IST.

**Conclusion**

The majority of the clinical data on use of ECP for cGVHD are derived from retrospective studies with limited numbers of patients. Most promising results appear to be for use in cutaneous cGVHD with most reports quoting an ORR of ~80%. \(^4\), \(^5\) The vast majority of published evidence on use of ECP for the treatment of cGVHD is focused on patients with SR or steroid-dependent cGVHD. There are very few studies currently available supporting the use of ECP as a first-line therapy of cGVHD. \(^5\) ECP is a highly attractive therapeutic modality for cGVHD given its excellent safety and overall tolerance profile, both in children and in adults. In addition, patients benefit from the lack of global immunosuppression and the preservation of the graft-versus-leukemia (GVL) effect. This favorable profile has encouraged leading experts in the field to suggest earlier use of ECP in the course of cGVHD, thus offering better control of GVHD and subsequently minimizing the risk of irreversible tissue damage and risk of death from systemic infections secondary to prolonged IST. Available data also suggested a survival advantage of ECP and improvement in the QoL. The issue remains that organ-specific response rates are variable with best responses observed in cutaneous, oral, ocular and possibly liver involvement. Responses for lung and GI involvement are less robust, and experience with ECP for cGVHD involving the lungs (bronchiolitis obliterans syndrome [BOS]) is limited. However, given the dismal prognosis of BOS, the efficacy of ECP for lung cGVHD still merits further investigation, and larger prospective studies are needed. To date, no specific treatment schedule has proven to be superior in terms of response rates making the collective interpretation of available literature difficult to assess. Thus, large, well-designed prospective studies are required to address these issues.

**Clinical experience in pediatrics**

Data on pediatric patients are limited to a few clinical reports using small numbers of patients. Performing ECP in pediatric patients is more complicated compared to adults due to challenges with vascular access, increased relative extracorporeal volumes, greater fluid shifts due to low body weight and psychological tolerance to procedure. However, ECP has been successfully utilized in children for both aGVHD and cGVHD.

In 2001, Salvaneschi et al \(^1\) treated 18 children with extensive cGVHD; they observed a 78% response rate and were able to wean steroids in 67% of patients. Messina et al \(^7\) treated 44 pediatric patients with cGVHD (considered extensive in 77% of patients). Significant improvement was observed in 59% of patients, and 44% of patients were able to discontinue all other IST. In 2007, Kanold et al \(^7\) published prospective data on the use of ECP for 27 pediatric patients with both aGVHD and cGVHD (12 and 15 patients, respectively), focusing on technical, biologic, immunologic, clinical and long-term follow-up issues. ORR was observed in 21 of 27 patients (11 with CR and 10 with PR) with few difficulties experienced by the investigators (with the main limiting factor being the vascular access). Authors concluded that ECP should be used as a first-line therapy in grade IV aGVHD, in addition to conventional pharmacological approaches, and in limited cGVHD. Furthermore, it should be considered as a second-line therapeutic modality in steroid-resistant grades II–III aGVHD and in extensive cGVHD.
Perotti et al\textsuperscript{58} performed a retrospective review of 23 pediatric patients with extensive cGVHD and found an ORR of 69.5%; organ-specific responses were 95%, 100%, 80% and 75% in cGVHD involving the skin, liver, oral mucosa and GI. Authors in this study suggest starting ECP at the onset of GVHD in addition to IST and continue ECP treatments until maximal response is achieved.

In an effort to counteract the challenge of treating pediatric patients with low bodyweight (as low as 15 kg) for both aGVHD and cGVHD, Schneiderman et al\textsuperscript{59} reported the use of a sterile, closed-loop procedure, where patients received fluid boluses of normal saline or 5% albumin to boost blood volume before and, if needed, during ECP procedures. The process was well tolerated by patients and therefore could extend the use of continuous-flow ECP to these patients with low body weight.

**Discussion**

Clinical use of ECP as a second-line therapeutic modality to treat GVHD has been extensively evaluated. However, most of these studies represent small case series or retrospective analyses that lack adequate control groups. Despite the abundance of clinical data spanning the last 3–4 decades, reaching a strong recommendation supported by high-quality evidence continues to be hampered by many confounding factors. Different studies have used a variety of ECP techniques on a variety of schedules for varying durations of time treating unknown quantities of PBMCs, all of which makes it challenging to assess the overall efficacy of this treatment modality. In addition, the lack of consensus on GVHD definitions, staging and response assessment make clinical outcomes difficult to interpret. Patient heterogeneity between studies further contributes to difficulty providing clear recommendations for when to optimally utilize this therapy.

Although different treatment options are available for second-line treatment of SR-GVHD, the choice of a particular therapeutic agent or treatment modality remains, to a large extent, a subject of treating physician’s preference, a choice that is usually based on factors such as safety profile, physician’s experience with the particular treatment and the presence of encouraging clinical data supporting its use. The safety profile of ECP is excellent. It is very well tolerated even in children with body weight as low as 10 kg.\textsuperscript{13,37,60} Several second-line therapies commonly used for SR-GVHD cause profound suppression of T-cell function (eg, ATG, alemtuzumab, daclizumab and pentostatin), thus significantly increasing the risk of viral reactivation in exposed patients. In contrast, ECP was found to have a favorable profile with limited toxicity, no increased risk for infections and no concerns for increased viral reactivations during ECP treatment.\textsuperscript{11,48,50}

This lack of global immunosuppression is particularly beneficial in patients who have undergone HCT for malignant diseases where preserving the GVL effect of donor T-lymphocytes is essential in eradicating the hematological malignancy. In fact, patients receiving ECP respond normally to new immune challenges such as exposure to pathogens or vaccines.\textsuperscript{62} ECP in patients with GVHD does not result in an increased incidence of malignant relapse, and patients undergoing long-term ECP therapy for CTCL and scleroderma do not develop the infections or secondary malignancies that are associated with conventional immunosuppressants.\textsuperscript{62,63}

Because intravenous access is required to perform ECP, patients are at risk for catheter-related complications including infection and thrombosis. Kanold et al\textsuperscript{57} reported that 2.5% (19 of 750) ECP procedures in 27 children were prematurely suspended due to CVL-related issues. Schneiderman et al observed 44 episodes (13%) of CVL occlusions that caused machine alarms. These were treated with normal saline flushes or TPA and required CVL change on two occasions.\textsuperscript{59}

Steroid sparing should be an important goal of second-line therapy, a feature that has not been consistently examined across ECP studies. One important consideration when using ECP especially for SR-cGVHD is the time needed to achieve an objective response. Data from large controlled studies support the notion that extended courses of ECP (beyond 12 weeks) may be necessary to achieve the desired response especially in patients with advanced cutaneous involvement (as in lichenoid and sclerodermoid cGVHD).\textsuperscript{48,49}

Some authors have suggested that earlier use of ECP improves response rates and increases the likelihood of being able to discontinue the use of steroids and other IST; however, this finding is inconsistent and needs further evaluation. Studies are ongoing to determine if early initiation of an aggressive ECP regimen provides additional disease control while limiting the need for additional IST. A randomized Phase II study for the evaluation of extracorporeal photopheresis (ECP) in combination with corticosteroids for the initial treatment of aGVHD was recently completed (NCT00609609). Another ongoing study is the Therakos trial (NCT02524847), which is a single-arm study aiming to assess the efficacy of Uvadex (Methoxsalen) in conjunction with the Therakos Cellex photopheresis system in pediatric patients with SR-aGVHD utilizing a novel, up-front aggressive ECP treatment regimen.
Summary

- Phases I and II data suggest that ECP is an effective treatment for aGVHD and cGVHD with response rates ranging from 40% to 81%. ECP is safe and well tolerated.5,13,50-52,64
- Response rates for cutaneous cGVHD are encouraging (~80%). Visceral and lung cGVHD responses have been less consistent across studies.44,55
- ECP has steroid-sparing properties; does not result in systemic immunosuppression; no reported increase in infectious complications in patients receiving ECP treatment; and no negative effect on GVL observed.
- No treatment frequency or duration of therapy has been proven to be ideal in improving response rates.
- The use of ECP as a second-line therapy is regarded as level C-1 strength of recommendation based on level II quality of evidence. Some evidence suggests that the earlier the ECP is administered, the greater the likelihood of achieving a CR/PR.50,56,65
- ECP may offer a survival benefit and improvement in QoL as well.66
- Large randomized trials are needed to better assess its efficacy and to answer questions such as when and for which patients should this therapy be offered.

Disclosure

Dr. Jacobsohn has received a consulting fee from Mallinckrodt (Cellnex ECP system) for the pediatric clinical trial development. The authors report no other conflicts of interest in this work.

References


